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Until now, it has usually been considered that the best 
way to diagnose and appropriately treat bacterial infec-
tion was to identify the bacteria(s) responsible for the 
infection. Th   is statement is accepted without debate for 
nearly all infections, whether they are severe (such as 
meningitis) or not (such as urinary tract infection). Th  e 
only question is about the delay for obtaining results with 
the necessity, in some cases, of initiating urgent empirical 
antibiotic treatment. In contrast, an endless debate exists 
about the diagnosis of ventilator-associated pneumonia 
(VAP). Th  is debate is not only about clinical evaluation 
alone versus clinical suspicion plus microbiological 
conﬁ   rmation, but also, in the case of bacteriologic 
diagnosis, about the choices between invasive and non-
invasive methods, bronchoscopic or non-bronchoscopic 
sampling techniques, and quantitative or non-quantitative 
bacterial cultures. Recently, the use of biomarkers has 
been proposed and tested to replace or complete (or 
both) such techniques [1-4]. VAP is diﬃ   cult to diagnose 
in the critically ill patient because of the presence of 
underlying cardiopulmonary disorders (for example, 
atelectasis, acute respiratory distress syndrome, 
congestive heart failure, pulmonary contusion, and 
pulmonary hemorrhage), the nonspeciﬁ  c  radio  graphic 
and clinical signs associated with this infection, and the 
rapid invasion of the normally sterile lower respiratory 
tract by microorganisms in all patients with an 
endotracheal tube, requiring that colonization be 
diﬀ  erentiated from true infection [2]. Actually, there is 
little information about actual clinical practice; individual 
studies indicate that practice often diﬀ  ers from recom-
men  dations in the literature [5]. In contrast, recom  men  ded 
design features of future clinical trials of antimicrobial 
agents for VAP – elaborated by the Infectious Disease 
Society of America, the American Th   oracic Society, the 
Society of Critical Care Medicine, and the American 
College of Chest Physicians – stress the requirement of 
appropriate microbiological conﬁ  rmation of infection by 
deep lower respiratory tract culture for inclusion in the 
intention-to-treat population of such trials [6].
Th  ese diﬃ   culties for diagnosing VAP and identifying 
responsible pathogen(s) lead to potential over- or under-
prescription of antibiotics and misguided treatment. Th  e 
strong associations between delayed diagnosis and sub-
sequent delayed initiation of treatment or between
inappropriate initial antibiotic therapy and worse 
outcome are well documented [7]. On the other hand, a 
recent observational study conducted in 303 patients at 
risk for multidrug-resistant pneumonia suggests that 
guideline-compliant antibiotic treatment was associated 
with increased mortality in comparison with non-
guideline-compliant treatment [8].
Th   e major potential advantage of biomarkers is not to 
diagnose VAP by itself but to potentially improve the 
rapidity and performance of current diagnostic proce-
dures. Th  e rationale is to identify and, if necessary, to 
dose speciﬁ  c markers of alveolar infection (not of bron-
chial colonization): either endogenous mediators released 
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Evaluation of a new biomarker from bronchoalveolar 
fl  uid, the Clara cell protein 10, adds data to the search 
for a diagnostic marker for ventilator-associated 
pneumonia (VAP). For more than 15 years, investigators 
tried to identify such a marker for predicting or 
diagnosing VAP. Unfortunately, the results of a number 
of these studies are disappointing. For optimal 
management of critically ill, ventilated patients with 
clinical suspicion of VAP, clinicians need accurate 
microbiological information to decide to treat in 
case of confi  rmed infection and to guide the initial 
choice of antibiotic therapy with identifi  cation of the 
responsible pathogen(s). Thus, today, the potential 
advantages of biomarkers are to improve the rapidity 
and performance of current diagnostic procedures and 
to reduce antibiotic exposure and selective pressure.
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© 2011 BioMed Central Ltdlocally by alveolar macrophages activated by microbial 
products or direct products of parenchymal destruction 
[9]. A number of biomarkers – including soluble trigger-
ing receptor expressed on myeloid cells-1 (sTREM-1) [10], 
procalcitonin (PCT) [11], co  peptin [12], C-reactive 
protein (CRP) [13], inter  leukin-1-beta, granulocyte 
colony-stimulating factor, macro  phage inﬂ  ammatory 
protein-1-alpha [14], plasminogen activa  tion inhibitor-1 
[15], surfactant protein D, receptor of advanced glycation 
end-products [16], midregional pro-atrial natriuretic 
peptide [17], and endotoxin [18] or elastin [19] ﬁ  bers – 
have been tested recently for use in determining the 
diagnosis and prognosis for patients with suspected or 
conﬁ  rmed VAP. Globally, the results of studies evaluating 
the value of biomarkers in diagnosing VAP are 
contradictory. Initially, biomarkers – particularly CRP, 
PCT, and sTREM-1 – were considered to be promising 
markers for improving diagnostic strategies of VAP. 
Today, the results of recent studies suggest that the 
measurement of biomarkers in bronchoalveolar lavage 
(BAL) ﬂ  uid appears to have minimal diagnostic value for 
VAP [13,20].
Th  e article by Vanspauwen and colleagues [1] in the 
previous issue of Critical Care adds new data to the 
search for a biomarker for VAP. Th   e investigators evalu-
ated a low-molecular-weight protein secreted in the 
alveoli, the Clara cell protein 10 (CC-10), which has a 
possible anti-inﬂ  ammatory role in humans [1]. Broncho-
scopy with BAL was performed in 196 patients who were 
treated with mechanical ventilation for more than 
48  hours and who had clinical suspicion of VAP. Th  e 
authors found, in the microbiologically conﬁ  rmed VAP 
group, a median CC-10 concentration that was signiﬁ  -
cantly higher than in the non-VAP group (3,019, range 
282 to 65,546 versus 2,054, range 62 to 30,240 ng/mL; 
P = 0.03), but such CC-10 levels are not discriminative 
for diagnosing VAP. No diﬀ  erence between patients with 
corticosteroids or antibiotic therapy and those without or 
between patients with Gram-positive and those with 
Gram-negative bacteria as responsible pathogens was 
observed.
In this well-conducted study, some strengths and weak-
nesses are worth mentioning. First, to evaluate new 
diagnostic techniques, a reference standard is required. 
For VAP, because histological conﬁ   rmation is not a 
practical reference, quantitative cultures of BAL ﬂ  uid are 
the best possible alternatives [2]. Second, bronchoscopy 
and lavage may be contraindicated in some patients and 
remain operator-dependent and time-consuming; in 
addition, high variability in the use of bronchoscopic 
sampling across intensive care units exists [5]. Th  ird,  an 
ideal diagnostic test for VAP would involve a highly 
discriminatory, easy-to-sample blood test. In fact, 
biomarkers potentially used in diagnosing VAP, including 
CC-10, are BAL-based techniques, just like quantitative 
cul  tures and direct examination of BAL ﬂ  uid.  Conse-
quently, such a new technique is probably an extension of 
BAL ﬂ   uid analysis in addition to microbiological 
techniques rather than a simpliﬁ   cation of diagnostic 
procedures for VAP. Fourth, as usual in this type of study, 
the precise timing of sampling may inﬂ  u  ence  the 
diagnosis of VAP. Results of CC-10 dosage in the group of 
non-VAP patients with a distinction between patients 
with negative cultures and those with more than 0 and 
less than 104 colony-forming units per milliliter (or less 
than 2% intracellular organisms) and data concerning the 
follow-up of such patients (particularly the occur  rence of 
subsequent pneumonia) could give additional 
information about the ability of CC-10 dosage to predict 
VAP. Finally, this study did not include sequential CC-10 
measurements, although recent data concerning PCT 
suggest that serial dosages may be used as a marker to 
monitor response and possibly to termi  nate antibiotic 
therapy [21]. Today, even if interest in surrogate markers 
(that is, BAL ﬂ   uid biomarker dosage) to resolve the 
question of diagnosing or predicting VAP is not demon-
strated, interest in the continuing story of biomarkers 
and VAP is certain.
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